Article Text

PDF
463 PHYSICAL INTERACTION BETWEEN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 AND ADIPONECTIN: IMPLICATIONS FOR INSULIN SENSITIVITY.
  1. A. Joshi,
  2. X. Yan,
  3. L. Cobb,
  4. P. Cohen,
  5. K. -W. Lee
  1. David Geffen School of Medicine at UCLA, Los Angeles, CA

Abstract

Background Obesity is a disease that has reached epidemic proportions; approximately one-third of the adult population in the US is obese. Obesity is a complex multifactorial, chronic disease that is often associated with the prevalence of insulin resistance and type 2 diabetes. Investigation into the mechanism of these diseases may elucidate a method for controlling diabetes. Insulin-like growth factor binding protein 3 (IGFBP-3) is the principal carrier of insulin-like growth factor (IGF) in serum and is found in most tissue types. Besides modulating IGF actions, IGFBP-3 also has IGF-independent roles. Type 1 alpha collagen is one of the recently identified binding partners of IGFBP-3. Furthermore a recent study suggests that chronic infusion of IGFBP-3 into rodents may induce insulin sensitivity. Adiponectin, an adipocytokine, is another factor that may be involved in insulin sensitivity and contains a collagenous domain.

Purpose of Study We hypothesized that IGFBP-3 and adiponectin may physically interact.

Methods Used In order to study this interaction, in vitro and in vivo studies were conducted using co-immunoprecipitation, radioligand, and dot blot techniques.

Summary of Results Results from the in vitro studies using radiolabeled IGFBP-3 and co-immunoprecipitation in serum showed that IGFBP-3 and adiponectin may directly interact. The results from in vivo studies using co-immunoprecipitation of IGFBP-3 and adiponectin in adipocytes showed similar interaction and provide a correlate to the in vitro data.

Conclusion We propose that the interface between IGFBP-3 and adiponectin may provide a basis for molecular investigation of obesity in rodent models and humans. This may involve interaction and prevention of adiponectin's insulin-sensitizing effect. Further study may lead to therapeutics in the treatment of obesity and type 2 diabetes.

Statistics from Altmetric.com

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.